← 返回

透明细胞肾细胞癌中 GFOD1 的表达及其在癌细胞增殖、迁移和侵袭中的作用

英文原题:GFOD1 expression in clear cell renal cell carcinoma and its role in cancer cell proliferation, migration, and invasion.

查看英文原题

GFOD1 expression in clear cell renal cell carcinoma and its role in cancer cell proliferation, migration, and invasion.

PubMed 2025/07/01(内容时间) Discov Oncol Q3 · IF 2.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

GFOD1 可能促进 KIRC 的增殖、迁移和侵袭。我们的发现可能为 KIRC 患者提供新的预后生物标志物和潜在的治疗靶点。

研究思路结论见上方概要

本研究旨在检测葡萄糖-果糖氧化还原酶结构域包含蛋白1(GFOD1)的表达水平,并探讨其在透明细胞肾细胞癌(ccRCC,又称KIRC)中对癌细胞增殖、迁移和侵袭的影响。

使用癌症基因组图谱(TCGA)数据库比较了GFOD1在各种肿瘤中的表达水平,以及单个肿瘤与其相邻组织之间GFOD1表达的差异。采用qRT-PCR和免疫组织化学评估了GFOD1在膀胱癌、KIRC、肾嫌色细胞癌、肾乳头状癌和前列腺癌中的表达。使用Kaplan-Meier方法分析了TCGA数据库中KIRC患者GFOD1的预后价值。还比较了不同KIRC分级和分期之间GFOD1表达的差异。transwell实验用于检测细胞转移能力的变化,并揭示上皮-间质转化(EMT)中的重要因素。对高表达基因进行基因本体论和京都基因与基因组百科全书通路富集分析,以探索GFOD1在ccRCC中的潜在作用。此外,评估了GFOD1与各种免疫亚群细胞之间的相关性,以探索潜在的免疫通路。

GFOD1在膀胱癌和KIRC中显著过表达。与GFOD1低表达患者相比,GFOD1表达升高的KIRC患者具有更好的总生存期(OS)和无病生存期(DFS)(P < 0.05)。此外,GFOD1表达与肿瘤分级呈负相关(P < 0.05)。敲低KIRC细胞中GFOD1的表达可增强细胞的增殖、迁移和侵袭潜能,并促进EMT。String蛋白互作分析显示,GFOD1与NKIRAS2、PHACTR1、HIVP1、HAO1及其他蛋白显著相关。这些基因的通路富集分析表明,GFOD1与多种离子通道激活通路、上皮(表皮)发育及细胞外基质胶原功能相关(P < 0.05)。此外,GFOD1与肿瘤组织中NK 细胞和CD8 + T细胞的富集相关。

展开英文摘要原文

The goal of this research was to examine the expression levels of Glucose-Fructose Oxidoreductase Domain Containing 1 (GFOD1) and to explore how it influences the proliferation, migration, and invasion of cancer cells in clear cell renal cell carcinoma (ccRCC, also known as KIRC).

The Cancer Genome Atlas (TCGA) database was used to compare GFOD1 expression levels across various tumors, as well as differences in GFOD1 expression between individual tumors and their adjacent tissues. The expression of GFOD1 in bladder cancer, KIRC, renal chromophobe cell carcinoma, renal papillary carcinoma, and prostate cancer was evaluated using qRT-PCR and immunohistochemistry. The prognostic value of GFOD1 in KIRC patients from the TCGA database was analyzed using the Kaplan-Meier method. Differences in GFOD1 expression among various KIRC grades and stages were also compared. The transwell assay served to detect variations in the metastatic ability of cells and to uncover important factors in epithelial-mesenchymal transition (EMT). Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis of highly expressed genes was performed to explore the potential role of GFOD1 in ccRCC. In addition, the correlation between GFOD1 and cells of various immune subsets was evaluated to explore potential immunological pathways.

GFOD1 was significantly overexpressed in bladder cancer and KIRC. KIRC patients with elevated GFOD1 expression had better overall survival (OS) and disease-free survival (DFS) compared to those with lower expression levels (P < 0.05). In addition, GFOD1 expression was negatively correlated with tumor grade (P < 0.05). Knocking-down the expression of GFOD1 in KIRC cells enhanced the proliferation, migration, and invasion potential of the cells and promoted EMT. String protein interaction analysis showed that GFOD1 was significantly correlated with NKIRAS2, PHACTR1, HIVP1, HAO1, and other proteins. Pathway enrichment analysis of these genes indicated that GFOD1 was associated with multiple ion channel activation pathways, epithelial (epidermal) development, and extracellular matrix collagen function (P < 0.05). Furthermore, GFOD1 was associated with enrichment of natural killer cells and CD8 + T cells in tumor tissues.

GFOD1 may promote the proliferation, migration, and invasion of KIRC. Our findings may provide new prognostic biomarkers and potential therapeutic targets for KIRC patients.

论文信息

作者
Liu Z、Wu K、Shu Q、Chen X
第一作者单位
Department of Urology, Division of Life Sciences and Medicine, The First Affiliated Hospital of University of Science and Technology of China, University of Science and Technology of China, Hefei, 230001, Anhui, China.China
通讯作者单位
Department of Urology, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230001, Anhui, China. chenxin704679314@163.com.China
期刊
Discover oncology2025 Jul 1
原文标识
PubMed 40591185 · DOI 10.1007/s12672-025-03049-2